Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Completes $8.7M Private Placement

NEW YORK, Sept. 17 (GenomeWeb News) -- Los Angeles-based CytRx today announced the completion of an $8.7 million private placement of its common stock.


The company, which trades its stock on the Nasdaq small cap exchange, said it sold 4.1 million shares to selected institutional investors, including current shareholders. Additionally, the company, which engages in biotechnology and drug-delivery, issued warrants for the purchase of an additional 1 million shares at an exercise price of $3.05 per share, and will register all of the privately placed shares for resale. The stock closed at $2.60 on Monday.


CytRx said it will use $7 million of the private-placement financing to expand its RNAi-based research and development efforts in obesity and type II diabetes, which it is conducting in collaboration with the University of Massachusetts Medical School. The company will create Araios, a fully-staffed operating subsidiary to develop an orally active drug for the treatment of the two conditions. Michael Czech, chairman of the department of molecular medicine at the University of Massachusetts, will serve as scientific advisor for the subsidiary.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.